Feb 26 (Reuters) - Bavarian Nordic A/S:
* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS
* BAVARIAN NORDIC AND ASTRAZENECA WILL CONTRIBUTE CLINICAL TRIAL MATERIAL AND PROVIDE FINANCIAL SUPPORT FOR PHASE 1/2
* NEW COLLABORATION THAT WILL INVESTIGATE CV301 AND DURVALUMAB (IMFINZI(TM)) Source text for Eikon: Further company coverage: (Gdynia Newsroom)